Search

Your search keyword '"French, Tim"' showing total 467 results

Search Constraints

Start Over You searched for: Author "French, Tim" Remove constraint Author: "French, Tim"
467 results on '"French, Tim"'

Search Results

53. Finding Minimum and Maximum Termination Time of Timed Automata Models with Cyclic Behaviour

55. A Modal Aleatoric Calculus for Probabilistic Reasoning

56. Aleatoric Dynamic Epistemic Logic for Learning Agents

59. Hourglass Automata

60. A composable language for action models

61. Knowledge, Awareness, and Bisimulation

62. Specifying Robustness

63. A Cooperative Coevolutionary Algorithm for Real-Time Underground Mine Scheduling

64. Teaching safety in design in large classes using VR

66. Refinement Modal Logic

70. A Novel Anonymity Quantification and Preservation Model for UnderNet Relay Networks

74. Supplementary Data from Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines

75. Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

76. Supplementary Table 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

77. Supplementary Table 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

78. Supplementary Figure 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

79. Supplementary Figure 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

80. Supplementary Figure 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

81. Supplementary Figure 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

82. Supplementary Figure 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

83. Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

84. Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

85. Data from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

86. Supplementary Table and Figure Legends from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

87. Supplementary Figure 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

88. Supplementary Table 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

89. Supplementary Table 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

90. Supplementary Table 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

91. Supplementary References from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

92. Supplementary Table 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

93. The Expressivity of Quantified Group Announcements

94. National Theatre Connections 2017: Three; #YOLO; Fomo; Status Update; Musical Differences; Extremism; The School Film; Zero for the Young Dudes!; The Snow Dragons; The Monstrum

95. Finding Best and Worst Case Execution Times of Systems Using Difference-Bound Matrices

97. The Expressivity of Quantified Group Announcements.

Catalog

Books, media, physical & digital resources